3-196487566-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_152617.4(RNF168):c.391C>T(p.Arg131Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000929 in 1,613,784 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_152617.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RNF168 | NM_152617.4 | c.391C>T | p.Arg131Ter | stop_gained | 3/6 | ENST00000318037.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RNF168 | ENST00000318037.3 | c.391C>T | p.Arg131Ter | stop_gained | 3/6 | 1 | NM_152617.4 | P1 | |
RNF168 | ENST00000437070.1 | c.314C>T | p.Ala105Val | missense_variant, NMD_transcript_variant | 2/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152006Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251260Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135824
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461778Hom.: 0 Cov.: 32 AF XY: 0.00000825 AC XY: 6AN XY: 727202
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152006Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74234
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 15, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 17, 2022 | This sequence change creates a premature translational stop signal (p.Arg131*) in the RNF168 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RNF168 are known to be pathogenic (PMID: 19203578, 21394101). This variant is present in population databases (rs201915239, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with RNF168-related conditions (PMID: 21394101). ClinVar contains an entry for this variant (Variation ID: 140755). For these reasons, this variant has been classified as Pathogenic. - |
RNF168-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 20, 2024 | The RNF168 c.391C>T variant is predicted to result in premature protein termination (p.Arg131*). This variant has been reported in the homozygous state in an individual with a phenotype consistent with RNF168-related disease (Devgan et al. 2011. PubMed ID: 21394101). Cultured cells from this individual exhibited poor survival following exposure to ionizing radiation, S-phase checkpoint defects, and an impaired response to DNA damage (Devgan et al. 2011. PubMed ID: 21394101). This variant has also been reported in the heterozygous state in an individual with pancreatic cancer who also possessed a heterozygous CFTR missense variant (CFTR: p.Gln1352His, Slavin et al. 2018. PubMed ID: 28687971). This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD. Nonsense variants in RNF168 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
RIDDLE syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2011 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at